Bridgeway Capital Management LLC Has $324,000 Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Bridgeway Capital Management LLC trimmed its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 60.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,400 shares of the medical instruments supplier's stock after selling 53,000 shares during the quarter. Bridgeway Capital Management LLC owned 0.09% of AngioDynamics worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ANGO. Balyasny Asset Management L.P. boosted its holdings in AngioDynamics by 77.8% in the 4th quarter. Balyasny Asset Management L.P. now owns 110,851 shares of the medical instruments supplier's stock valued at $1,015,000 after purchasing an additional 48,522 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of AngioDynamics by 24.0% in the fourth quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier's stock valued at $2,542,000 after buying an additional 53,675 shares during the period. Manatuck Hill Partners LLC grew its position in AngioDynamics by 166.0% during the fourth quarter. Manatuck Hill Partners LLC now owns 199,500 shares of the medical instruments supplier's stock worth $1,827,000 after buying an additional 124,500 shares in the last quarter. Northern Trust Corp grew its position in AngioDynamics by 2.4% during the fourth quarter. Northern Trust Corp now owns 351,365 shares of the medical instruments supplier's stock worth $3,219,000 after buying an additional 8,260 shares in the last quarter. Finally, Nebula Research & Development LLC bought a new position in AngioDynamics during the fourth quarter valued at about $125,000. Institutional investors and hedge funds own 89.43% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $16.00 price objective (up from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $9.57 on Tuesday. The firm has a market cap of $388.61 million, a P/E ratio of -1.70 and a beta of 0.58. The firm's 50-day simple moving average is $9.43 and its 200-day simple moving average is $9.35. AngioDynamics, Inc. has a twelve month low of $5.47 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company had revenue of $72.00 million for the quarter, compared to the consensus estimate of $70.30 million. The firm's revenue was down 4.3% compared to the same quarter last year. On average, equities analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.